Brainstorm Cell Therapeutics Inc (BCLI) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate that BMS’s newer‑product strategy can counteract legacy erosion, sustaining earnings growth while positioning the firm for continued market share gains in anticoagulation and oncology.

Key Takeaways

• Growth portfolio up 15% to $7.4 billion, 60% of revenue
• Total Q4 revenue flat at $12.5 billion, legacy decline $4 billion
• 2026 revenue guidance $46‑47.5 billion, Eliquis growth 10‑15%
• Breyanzi receives FDA approval for marginal zone lymphoma
• $1 billion cost‑savings delivered; another $1 billion planned

Pulse Analysis

BMS’s Q4 earnings underscore a pivotal shift toward a "growth‑first" portfolio, a trend echoed across the pharma industry as companies grapple with loss‑of‑exclusivity pressures. By expanding newer assets such as Opdualag, Breyanzi, and Camzyos, the firm not only recaptured a sizable share of its revenue base but also improved its gross margin profile, even though the mix‑induced margin dip to 71.9% reflects the weight of high‑volume, lower‑margin legacy drugs like Eliquis and Revlimid. The strategic price reduction on Eliquis, which eliminated inflationary rebates, is expected to sustain double‑digit growth and mitigate the impact of upcoming generic competition, a tactic other anticoagulant makers are watching closely.

Looking ahead, BMS’s guidance of $46‑47.5 billion for 2026 signals confidence in its pipeline and commercial execution. The company’s commitment to deliver six registrational readouts in the second half of 2026, including data for CAR‑T expansion and novel CELMoD candidates, could unlock additional revenue streams and reinforce its oncology leadership. Moreover, the $2 billion productivity initiative, with $1 billion already realized, highlights a broader industry focus on cost discipline and AI‑driven efficiencies to fund high‑risk R&D while preserving shareholder returns.

Investors should weigh the juxtaposition of robust growth‑portfolio momentum against lingering legacy headwinds. While the projected 10‑15% Eliquis expansion offers short‑term cushioning, the anticipated 12‑16% decline in other legacy brands and a $1.5‑2 billion revenue dip in 2027 due to global patent expiries present material risk. BMS’s ability to scale new launches, sustain pipeline productivity, and continue disciplined capital allocation will be critical determinants of its long‑term competitive positioning in a market increasingly driven by specialty therapeutics and biosimilar competition.